To examine the functional role of NF-κB, T98G and SNB19 glioma cell lines were treated with two different NF-κB inhibitors: a cell-permeable peptide inhibitor, SN50, and a small molecule inhibitor BAY-11-7082. This evidence concerns the gene NFKB1 and central nervous system cancer.